参考文献/References:
[1] Nakamura M, Kanbayashi T, Sugiura T, et al. Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels[J]. J Sleep Res, 2011, 20(1 Pt 1): 45-49.
[2] Rosenberg R, Kim AY. The AWAKEN survey: knowledge of narcolepsy among physicians and the general population[J]. Postgrad Med, 2014, 126(1): 78-86.
[3] Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality[J]. Curr Med Res Opin, 2016, 32(10):1611-1622.
[4] Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease(BOND)study[J]. Sleep Med, 2017, 33: 13-18.
[5] Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population[J]. Sleep Med, 2013, 14(6): 488-492.
[6] Carls G, Reddy SR, Broder MS, et al. Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities[J]. Sleep Med, 2020, 66:110-118.
[7] Bastianini S, Silvani A. Clinical implications of basic research: The role of hypocretin/orexin neurons in the central autonomic network[J]. Clinical and Translational Neuroscience, 2018, 2(2): 2514183X1878932.
[8] Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation[J]. Cell, 1999, 98(4): 437-451.
[9] Latorre D, Kallweit U, Armentani E, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons[J]. Nature, 2018, 562(7725): 63-68.
[10] Pizza F, Vandi S, Iloti M, et al. Nocturnal Sleep Dynamics Identify Narcolepsy Type 1[J]. Sleep, 2015, 38(8): 1277-1284.
[11] Sorensen GL, Knudsen S, Jennum P. Sleep transitions in hypocretin-deficient narcolepsy[J]. Sleep, 2013, 36(8): 1173-1177.
[12] Takei Y, Komada Y, Namba K, et al. Differences in findings of nocturnal polysomnography and multiple sleep latency test between narcolepsy and idiopathic hypersomnia[J]. Clin Neurophysiol, 2012, 123(1): 137-141.
[13] Vandi S, Rodolfi S, Pizza F, et al. Cardiovascular autonomic dysfunction, altered sleep architecture, and muscle overactivity during nocturnal sleep in pediatric patients with narcolepsy type 1[J]. Sleep, 2019, 42(12): zsz169.
[14] Alakuijala A, Sarkanen T, Partinen M. Hypocretin-1 Levels Associate with Fragmented Sleep in Patients with Narcolepsy Type 1[J]. Sleep, 2016, 39(5): 1047-1050.
[15] Grimaldi D, Silvani A, Benarroch EE, et al. Orexin/hypocretin system and autonomic control: new insights and clinical correlations[J]. Neurology, 2014, 82(3): 271-278.
[16] Li TL, Chen JYS, Huang SC, et al. Cardiovascular pressor effects of orexins in the dorsomedial hypothalamus[J]. Eur J Pharmacol, 2018, 818: 343-350.
[17] Jackson KL, Dampney BW, Moretti JL, et al. Contribution of Orexin to the Neurogenic Hypertension in BPH/2J Mice[J]. Hypertension, 2016, 67(5): 959-969.
[18] Iyer SH, Aggarwal A, Warren TJ, et al. Progressive cardiorespiratory dysfunction in Kv1.1 knockout mice may provide temporal biomarkers of pending sudden unexpected death in epilepsy(SUDEP): The contribution of orexin[J]. Epilepsia, 2020, 61(3): 572-588.
[19] Bastianini S, Silvani A, Berteotti C, et al. Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice[J]. Sleep, 2011, 34(2): 213-218.
[20] Widlansky ME, Gokce N, Keaney JF Jr, et al. The clinical implications of endothelial dysfunction[J]. J Am Coll Cardiol, 2003, 42(7): 1149-1160.
[21] Carreras A, Zhang SX, Peris E, et al. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice[J]. Sleep, 2014, 37(11): 1817-1824.
[22] Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells[J]. Cell, 1992, 71(2): 343-353.
[23] McAlpine CS, Kiss MG, Rattik S, et al. Sleep modulates haematopoiesis and protects against atherosclerosis[J]. Nature, 2019, 566(7744): 383-387.
[24] Perez MV, Pavlovic A, Shang C, et al. Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2 in Human Heart Failure[J]. J Am Coll Cardiol, 2015, 66(22): 2522-2533.
[25] Patel VH, Karteris E, Chen J, et al.Functional cardiac orexin receptors:role of orexin-B/orexin 2 receptor in myocardial protection[Z],2018:132.
[26] St-Onge MP, Grandner MA, Brown D, et al. Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association[J]. Circulation, 2016, 134(18): e367-e386.
[27] Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy[J]. J Clin Sleep Med, 2013, 9(9): 955-965.
[28] Vaz Fragoso CA, Miller ME, Fielding RA, et al. Sleep-wake disturbances in sedentary community-dwelling elderly adults with functional limitations[J]. J Am Geriatr Soc, 2014, 62(6): 1064-1072.
[29] Jaussent I, Empana JP, Ancelin ML, et al. Insomnia, daytime sleepiness and cardio-cerebrovascular diseases in the elderly: a 6-year prospective study[J]. PLoS One, 2013, 8(2): e56048.
[30] Barateau L, Lopez R, Chenini S, et al. Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence[J]. Neurology, 2020, 95(21): e2900-e2911.
[31] Blachier M, Dauvilliers Y, Jaussent I, et al. Excessive daytime sleepiness and vascular events: the Three City Study[J]. Ann Neurol, 2012, 71(5): 661-667.
[32] Empana JP, Dauvilliers Y, Dartigues JF, et al. Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: the three city study[J]. Stroke, 2009, 40(4): 1219-1224.
[33] Boden-Albala B, Roberts ET, Bazil C, et al. Daytime sleepiness and risk of stroke and vascular disease: findings from the Northern Manhattan Study(NOMAS)[J]. Circ Cardiovasc Qual Outcomes, 2012, 5(4): 500-507.
[34] Elwood P, Hack M, Pickering J, et al. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort[J]. J Epidemiol Community Health, 2006, 60(1): 69-73.
[35] Qureshi AI, Giles WH, Croft JB, et al. Habitual sleep patterns and risk for stroke and coronary heart disease: a 10-year follow-up from NHANES I[J]. Neurology, 1997, 48(4): 904-911.
[36] Cohen A, Mandrekar J, St Louis EK, et al. Comorbidities in a community sample of narcolepsy[J]. Sleep Med, 2018, 43:14-18.
[37] Jennum P, Ibsen R, Knudsen S, et al. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study[J]. Sleep, 2013, 36(6): 835-840.
[38] Poli F, Pizza F, Mignot E, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy[J]. Sleep, 2013, 36(2): 175-181.
[39] Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation [published correction appears in Eur Heart J. 2020 May 1; 41(17):1696] [J]. Eur Heart J, 2020, 41(17): 1687-1696.
[40] Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis[J]. Int J Obes(Lond). 2013; 37(8):1036-1043. doi:10.1038/ijo.2012.177.
[41] Inocente CO, Gustin MP, Lavault S, et al. Depressive feelings in children with narcolepsy[J]. Sleep Med, 2014, 15(3): 309-314.
[42] Huang TC, Tseng PT, Wu MN, et al. Periodic limb movements during sleep are associated with cardiovascular diseases: A systematic review and meta-analysis[J]. J Sleep Res, 2019, 28(3): e12720.
[43] Chenini S, Rassu AL, Guiraud L, et al. Blood pressure profile and endothelial function in restless legs syndrome[J]. Sci Rep, 2019, 9(1):15933.
[44] Filardi M, Demir N, Pizza F, et al. Prevalence and neurophysiological correlates of sleep disordered breathing in pediatric type 1 narcolepsy[J]. Sleep Med, 2020, 65: 8-12.
[45] Wyman L, Crum RM, Celentano D. Depressed mood and cause-specific mortality: a 40-year general community assessment[J]. Ann Epidemiol, 2012, 22(9): 638-643.